Search
Chicago, IL Paid Clinical Trials
A listing of 2029 clinical trials in Chicago, IL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1285 - 1296 of 2029
There are currently 2029 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Find the Best GLP-1 Weight Loss Providers (2025)
Recruiting
Cutting-edge GLP-1 treatments like semaglutide and tirzepatide are helping thousands lose weight with medically guided support. But with so many online providers, how do you know which programs are trusted, affordable, and right for you?
We reviewed the top GLP-1 brands of 2025 — comparing pricing, prescription process, shipping, pharmacy partners, and real user ratings — to help you find a safe, convenient, and effective path toward your weight-loss goals.
- 100% online programs
- Licensed U.S. clinicians
- Fast shipping & flexible payments
See the rankings & choose the GLP-1 provider that fits your life.
We reviewed the top GLP-1 brands of 2025 — comparing pricing, prescription process, shipping, pharmacy partners, and real user ratings — to help you find a safe, convenient, and effective path toward your weight-loss goals.
- 100% online programs
- Licensed U.S. clinicians
- Fast shipping & flexible payments
See the rankings & choose the GLP-1 provider that fits your life.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
ALS/MND Natural History Study Data Repository
Recruiting
This is a data repository for multi-site multi-protocol clinic-based Natural History Study of ALS and Other Motor Neuron Disorders (MND).
All people living with ALS or other MNDs who attend clinics at the Study hospitals (sites) are offered to participate in the Study.
The Sites collect so-called Baseline information including demographics, disease history and diagnosis, family history, etc. At each visit, the Sites also collect multiple disease-specific outcome measures and events. The inform... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/23/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy, PBP - Progressive Bulbar Palsy
Surgical Approach to Uterine Septum
Recruiting
The objective of this study is to determine if the use of scissors without electrosurgery is superior to bipolar electrosurgery for resection of uterine septum. The investigators will be comparing procedure-level variables such as operative time, complications, and need for additional procedures.
Gender:
FEMALE
Ages:
Between 22 years and 44 years
Trial Updated:
04/23/2025
Locations: Northwestern Medicine Prentice Women's Hospital, Chicago, Illinois
Conditions: Uterine Septum, Surgical Complication, Septum; Uterus, Treatment Side Effects, Treatment
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Progressive Pulmonary Fibrosis
Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function
Recruiting
This is a pilot study to assess using validated outcome measures how ingesting pumpkin seed oil extract supports patient bladder function in a United States population.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Overactive Bladder (OAB)
Conditioning SCID Infants Diagnosed Early
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: Comer Children's Hospital/University of Chicago Medicine, Chicago, Illinois
Conditions: SCID
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Recruiting
This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/22/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
Recruiting
The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation.
The question being addressed is: can laboratory work, anthropometric tests, functional tests, imaging, and advanced measurements such as wrist actigraphy, continuous glucose monitoring, or oral glucose tolerance testing predict the development of diabetes after liver transplant?
Participants will be asked to periodica... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Cirrhosis, Liver, Diabetes Mellitus Risk, Transplant; Failure, Liver, Transplant-Related Disorder
DALY II USA/ MB-CART2019.1 for DLBCL
Recruiting
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Robert H Lurie Cancer Center, Chicago, Illinois
Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation
Improving the Health and Social Participation of People With Disabilities From Underrepresented Groups Post COVID
Recruiting
This is a single-arm community-based feasibility study examining recruitment, retention, adherence, and satisfaction with ENGAGE, a community-based intervention designed to address pandemic-related social isolation among people with disabilities. We will also examine preliminary, within-group effects on social participation. The findings of this study will inform a larger trial to examine intervention efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Disabilities Multiple
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Peripartum Cardiomyopathy, Postpartum
Nephrotic Syndrome Study Network
Recruiting
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not s... Read More
Gender:
ALL
Ages:
80 years and below
Trial Updated:
04/18/2025
Locations: John Stroger Cook County Hospital, Chicago, Illinois
Conditions: Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
Recruiting
This phase II trial studies the effect of megestrol acetate alone or in combination with metformin in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer. Megestrol acetate is a drug used to block estrogen and suppress the effects of estrogen and androgens. It is the current non-surgical treatment of endometrial intraepithelial neoplasia. Metformin is a drug that has been found to have anti-cancer properties. Giving metformin and megestr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Endometrial Carcinoma, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
1285 - 1296 of 2029
